The oldest known reference to male breast cancer (MBC)- although the word cancer was not used-has been found in an Egyptian manuscript on trauma surgery, the Edwin Smith Papyrus, around 3000-2500 BC. The Greek physician Hippocrates (460-370 BC) used the term carcinoma to describe the “crab-like” spreading pattern of certain tumors, which roman physician Celsus (28-50 BC) translated into cancer.
Soft tissue sarcomas are a heterogeneous group of malignant neoplasms derived from mesenchymal cells. Breast sarcomas are rare, representing less than 1% of all breast cancers and less than 5% of all soft tissue sarcomas. The subtype of sarcoma strongly linked to the breast is the angiosarcoma, originating in the endothelial vascular or lymphatic cells. It is usually aggressive, with rapid proliferation and infiltration into the surrounding tissues.
As a malignant disease, cancer causes a large number of deaths worldwide every year due to its high morbidity and high fatality rate. According to the global cancer statistics report provided by the World Health Organization (WHO), there were 18.1 million new cancer cases and 9.6 million deaths worldwide in 2018. In 91 of the 172 countries around the world, cancer has surpassed cardiovascular and cerebrovascular diseases and become the leading cause of human death.
Cancer is an abnormal cell growth where cells tend to proliferate in an uncontrolled way, loss their normal function and can spread through blood at all the body. There are more than 200 types of cancer, each with different causes and symptoms. Personal risk of developing cancer depends on a variety of factors including age, lifestyle and genetics.
Nasopharyngeal Carcinoma (NPC) is very rare in children less than 10-years [1]. It constitutes to 1% of all pediatric malignancies and 35-50% of nasopharyngeal malignancies in children [2]. It usually arises from the Rosenmullar fossa of nasopharynx. NPC can invade the base of skull and commonly presents with bilateral cervical lymphadenopathy. Distant metastases are rare at presentation. NPC being chemo and radiosensitive tumor, both modalities are used currently in the management of these patients.
We always work towards offering the best to you. For any queries, please feel free to get in touch with us. Also you may post your valuable feedback after reading our journals, ebooks and after visiting our conferences.
